Reuters logo
Nabriva's pneumonia drug meets main goal in late-stage study
September 18, 2017 / 11:26 AM / 3 months ago

Nabriva's pneumonia drug meets main goal in late-stage study

Sept 18 (Reuters) - Nabriva Therapeutics Plc said on Monday its experimental treatment for community-acquired bacterial pneumonia met the main goal in a late-stage study, sending its shares up more than 70 percent in premarket trading.

Community-acquired bacterial pneumonia is the leading cause of infectious death in the United States. (Reporting by Manas Mishra in Bengaluru; Editing by Anil D‘Silva)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below